Aligos Therapeutics (ALGS) Short Interest Ratio & Short Volume $5.82 +0.19 (+3.45%) As of 01:46 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Aligos Therapeutics Short Interest DataAligos Therapeutics (ALGS) has a short interest of 835,700 shares, representing 20.79% of the float (the number of shares available for trading by the public). This marks a 0.44% increase in short interest from the previous month. The short interest ratio (days to cover) is 4.5, indicating that it would take 4.5 days of the average trading volume of 198,870 shares to cover all short positions.Current Short Interest835,700 sharesPrevious Short Interest832,000 sharesChange Vs. Previous Month+0.44%Dollar Volume Sold Short$4.66 millionShort Interest Ratio4.5 Days to CoverLast Record DateApril 30, 2025Outstanding Shares6,114,000 sharesFloat Size4,020,000 sharesShort Percent of Float20.79%Today's Trading Volume36,696 sharesAverage Trading Volume198,870 sharesToday's Volume Vs. Average18% Short Selling Aligos Therapeutics? Sign up to receive the latest short interest report for Aligos Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartALGS Short Interest Over TimeALGS Days to Cover Over TimeALGS Percentage of Float Shorted Over Time Aligos Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/30/2025835,700 shares $4.66 million +0.4%20.8%4.5 $5.58 4/15/2025832,000 shares $3.93 million +1.0%20.7%4 $4.72 3/31/2025823,600 shares $6.79 million +3.6%20.6%3.5 $8.25 3/15/2025795,300 shares $9.10 million +10.1%19.9%2.8 $11.44 2/28/2025722,400 shares $12.19 million +1.3%27.4%2.2 $16.87 2/15/2025713,000 shares $16.88 million +23.7%27.0%2 $23.67 1/31/2025576,400 shares $14.87 million -13.3%21.8%1.2 $25.80 1/15/2025664,400 shares $21.08 million +11.2%25.2%1.5 $31.73 12/31/2024597,300 shares $23.80 million +30.7%22.4%1.4 $39.84 12/15/2024457,100 shares $15.57 million +61.1%17.1%1.3 $34.07 Get the Latest News and Ratings for ALGS and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Aligos Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 11/30/2024283,800 shares $7.24 million -2.6%11.2%0.9 $25.51 11/15/2024291,500 shares $5.59 million +140.3%11.5%1.1 $19.17 10/31/2024121,300 shares $1.19 million +46.5%4.8%0.8 $9.78 10/15/202482,800 shares $601,956.00 -31.0%3.7%1.3 $7.27 9/30/2024120,000 shares $1.04 million +245.8%5.3%2 $8.66 9/15/202434,700 shares $513,560.00 +132.9%1.5%0.6 $14.80 8/31/202414,900 shares $188,932.00 +18.3%0.7%0.4 $12.68 8/15/202412,600 shares $151,231.50 -95.5%0.6%0.6 $12.00 7/31/2024281,100 shares $146,172.00 +13.1%N/A0.7 $0.52 7/15/2024248,500 shares $126,710.15 -88.5%N/A0.6 $0.51 6/30/20242,160,000 shares $756,000.00 +16.8%N/A5.6 $0.35 6/15/20241,850,000 shares $925,000.00 -0.5%N/A6.2 $0.50 5/31/20241,860,000 shares $1.10 million +69.1%N/A6 $0.59 5/15/20241,100,000 shares $747,010.00 +31.2%N/A2.9 $0.68 4/30/2024838,500 shares $641,452.50 +27.6%N/A2.2 $0.77 4/15/2024657,200 shares $587,996.84 -24.4%N/A1.7 $0.89 3/31/2024868,800 shares $851,424.00 +137.6%N/A2.3 $0.98 3/15/2024365,600 shares $336,900.40 -1.0%N/A0.9 $0.92 2/29/2024369,100 shares $365,409.00 +16.4%N/A0.8 $0.99 2/15/2024317,100 shares $203,578.20 -64.6%N/A0.8 $0.64 1/31/2024894,500 shares $617,205.00 +6.4%N/A3 $0.69 1/15/2024840,400 shares $619,458.84 -1.7%N/A2.8 $0.74 12/31/2023855,200 shares $567,852.80 -1.1%N/A3.1 $0.66 12/15/2023864,400 shares $505,760.44 +14.2%N/A4.1 $0.59 11/30/2023756,900 shares $529,830.00 +4.4%2.4%4.6 $0.70 11/15/2023724,800 shares $456,624.00 -1.3%2.3%9.2 $0.63 10/31/2023734,600 shares $440,760.00 -3.4%4.1%10.1 $0.60 10/15/2023760,700 shares $562,918.00 +1.0%2.8%10.8 $0.74 9/30/2023753,300 shares $562,715.10 -1.6%2.8%10.7 $0.75 9/15/2023765,200 shares $612,160.00 +0.6%2.9%10.1 $0.80Trump + Musk = AI’s turning point (Ad)Trump may not code… but he knows how to pick winners. And according to insiders, his administration is preparing to fast-track a new class of AI infrastructure tech. Elon Musk has already poured $51 million into it.Chris Rowe just shared the full details in a live presentation… Watch it here before it comes down. 8/31/2023761,000 shares $655,221.00 +2.6%2.9%7.7 $0.86 8/15/2023742,100 shares $693,863.50 -4.5%2.8%6.9 $0.94 7/31/2023776,800 shares $691,352.00 -3.3%2.8%3.5 $0.89 7/15/2023803,500 shares $827,605.00 -1.7%2.9%3.8 $1.03 6/30/2023817,600 shares $793,889.60 +4.1%3.0%3.9 $0.97 6/15/2023785,700 shares $864,270.00 -14.3%2.9%3.7 $1.10 5/31/2023917,000 shares $1.04 million +25.0%3.4%4.5 $1.13 5/15/2023733,500 shares $953,550.00 -5.3%2.7%3.6 $1.30 4/30/2023774,500 shares $898,420.00 -0.3%2.8%7.7 $1.16 4/15/2023776,800 shares $722,346.32 -6.8%2.8%5.8 $0.93 3/31/2023833,000 shares $728,042.00 -4.4%3.0%2.8 $0.87 3/15/2023871,200 shares $1.17 million +2.0%3.3%2.2 $1.34 2/28/2023853,900 shares $1.25 million +16.2%2.9%2.1 $1.46 2/15/2023735,100 shares $1.19 million +0.7%2.5%1.8 $1.62 1/31/2023730,300 shares $1.42 million +128.4%2.7%1.8 $1.94 1/15/2023319,800 shares $524,472.00 -17.6%1.2%0.9 $1.64 12/30/2022387,900 shares $369,629.91 -3.5%1.4%1.8 $0.95 12/15/2022402,100 shares $381,995.00 +3.2%1.5%4.6 $0.95 11/30/2022389,500 shares $389,500.00 -7.1%1.4%5.2 $1.00 11/15/2022419,300 shares $427,686.00 +17.6%1.5%5.7 $1.02 10/31/2022356,700 shares $374,535.00 +1.1%1.6%4.8 $1.05 10/15/2022353,000 shares $388,300.00 +4.6%1.6%4.5 $1.10 9/30/2022337,600 shares $371,360.00 -13.5%1.5%3.4 $1.10 9/15/2022390,300 shares $519,099.00 +11.7%1.7%2.6 $1.33 8/31/2022349,300 shares $436,625.00 -20.2%1.6%2.1 $1.25 8/15/2022437,800 shares $682,968.00 -13.3%2.0%2.1 $1.56 7/31/2022505,000 shares $626,200.00 -17.9%2.3%1.7 $1.24 7/15/2022614,800 shares $965,236.00 -72.4%2.8%1.9 $1.57 6/30/20222,230,000 shares $2.70 million -22.0%10.0%6.8 $1.21 6/15/20222,860,000 shares $3.75 million -3.4%12.9%7.8 $1.31 5/31/20222,960,000 shares $3.82 million +2.1%12.6%8.3 $1.29 5/15/20222,900,000 shares $3.39 million +11.5%12.3%7.8 $1.17 4/30/20222,600,000 shares $3.07 million +7.9%10.3%7.4 $1.18 4/15/20222,410,000 shares $3.74 million +4.8%9.5%5.7 $1.55 3/31/20222,300,000 shares $4.95 million +3.1%9.1%4 $2.15 3/15/20222,230,000 shares $5.26 million +5.7%8.8%4.1 $2.36 2/28/20222,110,000 shares $5.11 million +0.5%8.4%4.1 $2.42 2/15/20222,100,000 shares $5.54 million +3.5%8.3%4.3 $2.64 1/31/20222,030,000 shares $6.48 million +6.3%8.0%4.3 $3.19 1/15/20221,910,000 shares $6.49 million -15.5%7.3%5.4 $3.40 12/31/20212,260,000 shares $26.83 million +3.7%8.7%8.3 $11.87 12/15/20212,180,000 shares $27.14 million +2.8%8.4%11.9 $12.45 11/30/20212,120,000 shares $32.48 million +10.4%8.1%10.5 $15.32 11/15/20211,920,000 shares $32.35 million -3.5%7.4%9.6 $16.85 10/29/20211,990,000 shares $31.70 million +2.6%7.8%10.1 $15.93 10/15/20211,940,000 shares $30.87 million +2.1%7.6%9.3 $15.91 9/30/20211,900,000 shares $29.47 million +9.2%7.4%7.8 $15.51 9/15/20211,740,000 shares $28.28 million -3.3%6.8%5.6 $16.25 8/31/20211,800,000 shares $30.69 million -3.2%7.0%6.8 $17.05 8/13/20211,860,000 shares $29.24 million +1.1%7.3%7.2 $15.72Trump + Musk = AI’s turning point (Ad)Trump may not code… but he knows how to pick winners. And according to insiders, his administration is preparing to fast-track a new class of AI infrastructure tech. Elon Musk has already poured $51 million into it.Chris Rowe just shared the full details in a live presentation… Watch it here before it comes down. 7/30/20211,840,000 shares $26.81 million +4.6%7.7%7.3 $14.57 7/15/20211,760,000 shares $27.24 million +2.9%7.3%8.2 $15.48 6/30/20211,710,000 shares $34.86 million +9.6%7.1%9 $20.39 6/15/20211,560,000 shares $44.43 million -0.6%7.2%18.2 $28.48 5/28/20211,570,000 shares $43.77 million -2.5%7.4%22.2 $27.88 5/14/20211,610,000 shares $36.40 million -1.2%8.2%25.2 $22.61 4/30/20211,630,000 shares $44.17 million +1.9%8.4%26.3 $27.10 4/15/20211,600,000 shares $34.53 million +3.2%7.8%24.1 $21.58 3/31/20211,550,000 shares $32.35 million No Change7.5%23 $20.87 3/15/20211,550,000 shares $40.52 million +3.3%7.5%13.2 $26.14 2/26/20211,500,000 shares $42.09 million +10.3%7.3%9.8 $28.06 2/12/20211,360,000 shares $31.73 million +3.8%6.6%8.3 $23.33 1/29/20211,310,000 shares $34.56 million +4.0%6.1%7.5 $26.38 1/15/20211,260,000 shares $43.02 million No Change5.8%6.8 $34.14 ALGS Short Interest - Frequently Asked Questions What is Aligos Therapeutics' current short interest? Short interest is the volume of Aligos Therapeutics shares that have been sold short but have not yet been covered or closed out. As of April 30th, investors have sold 835,700 shares of ALGS short. 20.79% of Aligos Therapeutics' shares are currently sold short. Learn More on Aligos Therapeutics' current short interest. What is a good short interest ratio for Aligos Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. ALGS shares currently have a short interest ratio of 4.0. Learn More on Aligos Therapeutics's short interest ratio. What is a good short interest percentage for Aligos Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 20.79% of Aligos Therapeutics' floating shares are currently sold short. Is Aligos Therapeutics' short interest increasing or decreasing? Aligos Therapeutics saw a increase in short interest in the month of April. As of April 30th, there was short interest totaling 835,700 shares, an increase of 0.4% from the previous total of 832,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Aligos Therapeutics' float size? Aligos Therapeutics currently has issued a total of 6,114,000 shares. Some of Aligos Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Aligos Therapeutics currently has a public float of 4,020,000 shares. How does Aligos Therapeutics' short interest compare to its competitors? 20.79% of Aligos Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Aligos Therapeutics: Aclaris Therapeutics, Inc. (4.11%), Fate Therapeutics, Inc. (11.64%), Eupraxia Pharmaceuticals Inc. (0.50%), Greenwich LifeSciences, Inc. (16.77%), Protara Therapeutics, Inc. (6.43%), FitLife Brands, Inc. (0.26%), RAPT Therapeutics, Inc. (2.71%), Enanta Pharmaceuticals, Inc. (14.93%), Atossa Therapeutics, Inc. (5.52%), Alector, Inc. (7.09%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Spotify Technology S.A. ($4.67 billion), Charter Communications, Inc. ($4.58 billion), Capital One Financial Co. ($4.47 billion), The Kroger Co. ($2.56 billion), Reddit, Inc. ($2.23 billion), Rivian Automotive, Inc. ($2.16 billion), Live Nation Entertainment, Inc. ($1.90 billion), SoFi Technologies, Inc. ($1.85 billion), Zscaler, Inc. ($1.75 billion), and Omnicom Group Inc. ($1.75 billion). View all of the most shorted stocks. What does it mean to sell short Aligos Therapeutics stock? Short selling ALGS is an investing strategy that aims to generate trading profit from Aligos Therapeutics as its price is falling. ALGS shares are trading up $0.19 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Aligos Therapeutics? A short squeeze for Aligos Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of ALGS, which in turn drives the price of the stock up even further. How often is Aligos Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including ALGS, twice per month. The most recent reporting period available is April, 30 2025. More Short Interest Resources from MarketBeat Related Companies Aclaris Therapeutics Short Squeeze Fate Therapeutics Short Squeeze Eupraxia Pharmaceuticals Short Squeeze Greenwich LifeSciences Short Squeeze Protara Therapeutics Short Squeeze FitLife Brands Short Squeeze RAPT Therapeutics Short Squeeze Enanta Pharmaceuticals Short Squeeze Atossa Therapeutics Short Squeeze Alector Short Squeeze Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:ALGS) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredAI Bloodbath Coming on June 1st?If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredThe Collapse Has Already Started — Your 401(k) Is NextThere's a major heist happening on American wealth in real time. Except this one doesn't involve masks or v...American Hartford Gold | SponsoredElon’s 2025 Silver Crisis (What It Means for You)Elon Musk is back in the spotlight—this time for fueling a global scramble for silver. Tesla's relentless p...GoldenCrest Metals | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredTrump’s Bitcoin Reserve is No Accident…How everyday investors are building crypto wealth (step-by-step guide) Don't wait. The window for maximum g...Crypto 101 Media | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aligos Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aligos Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ALGS Stock Free ALGS Stock Alerts